{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:15:16Z","timestamp":1787505316754,"version":"build-2736575974"},"reference-count":26,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"National Cancer Institute, National Institutes of HealthNational Cancer Institute, National Institutes of Health","award":["HHSN2616200800001E"],"award-info":[{"award-number":["HHSN2616200800001E"]}]},{"name":"National Institutes of Allergy and Infectious Disease","award":["Intramural"],"award-info":[{"award-number":["Intramural"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2016,3,23]]},"DOI":"10.1517\/14656566.2016.1157580","type":"journal-article","created":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T01:50:49Z","timestamp":1456105849000},"page":"743-749","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Sofosbuvir and ledipasvir for HIV\/HCV co-infected patients"],"prefix":"10.1517","volume":"17","author":[{"given":"Elana S.","family":"Rosenthal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Kottilil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Polis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,3,16]]},"reference":[{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1086\/321909"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1002\/lt.23411"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-014-9606-9"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1505967"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.051"},{"key":"CIT0013","volume-title":"(HCV-TARGET) - treatment outcomes with 8, 12 and 24 week regimens of ledipasvir\/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study. AASLD","author":"Terrault NA","year":"2015"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27934"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"issue":"4","key":"CIT0016","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/civ897","volume":"62","author":"Kattakuzhy S","year":"2016","journal-title":"Clin Infect Dis"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ874"},{"key":"CIT0018","volume-title":"Retreatment of patients who failed 8 or 12 weeks of ledipasvir\/sofosbuvir-based regimens with ledipasvir\/sofosbuvir for 24 weeks. EASL - The International Liver Congress 2015","author":"Lawitz E","year":"2015"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1373"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000185"},{"key":"CIT0022","volume-title":"Pharmacokinetic analyses of ledipasvir\/sofosbuvir and HIV antiretroviral regimens in subjects with HCV\/HIV coinfection. AASLD 2015","author":"German P","year":"2015"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.6621"},{"key":"CIT0026","unstructured":"Genvoya [package insert]. Foster City, CA: Gilead Sciences; 2015."},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1328"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503153"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00114-9"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ677"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0406"},{"key":"CIT0032","volume-title":"Incidence and determinants of denial of DAA treatment for chronic HCV infection by insurance type during the first 6 months of the modern HCV treatment era. AASLD 2015","author":"Lo Re V","year":"2015"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.01.004"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.2016.1157580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T09:15:16Z","timestamp":1748769316000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.2016.1157580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,16]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,3,21]]},"published-print":{"date-parts":[[2016,3,23]]}},"alternative-id":["10.1517\/14656566.2016.1157580"],"URL":"https:\/\/doi.org\/10.1517\/14656566.2016.1157580","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}